The clinical effectiveness of pneumococcal vaccination: A brief review

Vaccine

Volumn 17, Issue SUPPL. 1, 1999, Pages

  Fedson, David S ^a  

^a Pasteur Merieux Connaught   (France)

Author keywords

Clinical effectiveness; Pneumococcal vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INFECTION RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0033618419     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00113-9     Document Type: Conference Paper

References (36)

1. Simberkoff MS. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness. Semin Respir Infect 1993;8:294-9.
2. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med 1994;154:373-7.
3. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, Reid RDW. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89:184-94.
4. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6.
5. Gaillat J, Zmirou D, Mallaret M, Rouhan D, Bru JP, Stahl J, Delormas P, Micoud M. Clinical trial of pneumococcal vaccine among institutionalized elderly [French]. Rev Epidémiol Santé Publ 1985;33:437-44.
6. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;315:1318-27.
7. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-90.
8. Ortqvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, Lindblad I, Sundelof B, Kalin M. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in the prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403.
9. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
10. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Respir Infect 1993;8:285-93.
11. Jalonen E, Paton JC, Koskela M, Kerttula Y, Leinonen M. Measurement of antibody responses to pneumolysin - a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect 1989;19:127-34.
12. Leinonen M, Syrjala H, Jalonen E, Kujala P, Herva E. Demonstration of pneumolysin antibodies in dissociated immune complexes - A new method for etiological diagnosis of pneumococcal pneumonia. Serodiag Immunother Infect Dis 1990;4:451-8.
13. Korppi M, Koskela M, Jalonen E, Leinonen M. Serologically indicated pneumococcal respiratory infection in children. Scand J Infect Dis 1992;24:437-43.
14. Fedson DS, Shapiro ED, LaForce FM, Mufson MA, Musher DM, Spika JS, Breiman RF, Broome CV. Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med 2994;154:2531-5.
15. Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis 1984;6:589-600.
16. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994;16:77-89.
17. Fedson DS. Measuring protection: efficacy versus effectiveness. In: Brown F, Plotkin SA, editors. Preclinical and clinical development of new vaccines. Dev Biol Stand. Basel: Karger. 1998. p. 195-201.
18. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984;101:325-30.
19. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987;83:425-30.
20. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988;108:653-7.
21. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
22. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. Epidemiology of invasive pneumococcal disease - Reply. J Infect Dis 1995;171:1065-6.
23. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, Anglim AM. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995;155:2336-40.
24. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270:1826-31.
25. Fedson DS, Scott JAG, The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999; Suppl.1:511-518.
26. Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, Plouffe JF, Cetron MS, Butler JC. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9.
27. Hak E, van Essen GA, Grobbee DE, Verheij TJM. Effectiveness of pneumococcal vaccine (letter). Lancet 1998;351:1283.
28. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995;21:616-20.
29. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997;176:1100-4.
30. Centers for Disease Control and Prevention. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR8):1-24.
31. Rodriguez R, Dyer PD. Safety of pneumococcal revaccination. J Gen Intern Med 1995;10:511-2.
32. Jackson LA, Benson P, Sneller V-P, Butler J, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, Lezhava T, Williams WW. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-8.
33. Black S, Shinefield H, Ray P, Lewis E, Fireman B, The Kaiser Permanente Vaccine Study Group, Austrian R, Siber G, Hackell J, Kohberger R, Chang I. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial (abstract LB9). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, Sept. 24-27 1998.
34. Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, Shamberger RC, Phillips NR, Goorin A, Ambrosino DM. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996;173:256-8.
35. Antilla M, Eskola J, Kayhty H. Opsonic activity and concentration of antibodies to Streptococcus pneumoniae type 6B polysaccharide (Abstract). 35th Annual Meeting of the Infectious Diseases Society of America, 1997; p. 183.
36. Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. Clin Infect Dis 1998;26:1117-23.